GlaxoSmithKline

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Established: 1929-01-01

Employees: 70.2K

Market Cap: $90B

Website: http://www.gsk.com

Introduction: GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Clinical Trials

Investigation Of A New Medication (GW642444) In Asthmatic Patients

Phase 2

Completed

Conditions: Asthma

Interventions: Drug: GW642444
Drug: salmeterol 50mcg
Drug: Placebo

First Posted Date: 2006-07-20

Last Posted Date: 2016-09-15

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 28

Registration Number: NCT00354874

Locations: 🇸🇪
GSK Investigational Site, Göteborg, Sweden

Single Doses GSK159797 On Patient Safety And Lung Function In Patients With Mild To Moderate Asthma

Phase 2

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

First Posted Date: 2006-07-20

Last Posted Date: 2016-09-01

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 20

Registration Number: NCT00354666

Pharmacokinetic Profiles Of Amoxicillin 2000 mg And Clavulanate 125 mg In Adolescent Patients

Phase 1

Completed

Conditions: Infections, Respiratory Tract

Interventions: Drug: amoxicillin/clavulanate potassium

First Posted Date: 2006-07-20

Last Posted Date: 2017-08-01

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 52

Registration Number: NCT00354965

Locations: 🇺🇸
GSK Investigational Site, Erie, Pennsylvania, United States

In-patient Study With GSK716155 In Patients With Type 2 Diabetes Mellitus

Phase 2

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Biological: placebo injection
Drug: GSK716155 subcutaneous injections

First Posted Date: 2006-07-20

Last Posted Date: 2016-10-26

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 60

Registration Number: NCT00354536

Locations: 🇺🇸
GSK Investigational Site, San Antonio, Texas, United States

Evaluation of A Morning Dosing Of A New Medicine And Its Effects On Sleep At Bedtime In Subjects With Primary Insomnia

Phase 2

Completed

Conditions: Insomnia
Sleep Initiation and Maintenance Disorders

First Posted Date: 2006-07-20

Last Posted Date: 2015-04-16

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 68

Registration Number: NCT00354809

Locations: 🇩🇪
GSK Investigational Site, Berlin, Germany

Seretide Versus Flixotide In Asthmatic Children Not Controlled By Inhaled Corticosteroids

Phase 4

Completed

Conditions: Asthma

Interventions: Drug: Fluticasone propionate
Drug: Fluticasone propionate/salmeterol

First Posted Date: 2006-07-19

Last Posted Date: 2018-05-29

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 506

Registration Number: NCT00353873

Locations: 🇸🇪
GSK Investigational Site, Stockholm, Sweden

Immunogenicity, Safety of Measles-mumps-rubella-varicella Vaccine (MeMuRu-OKA) Compared to Priorix™ Given With Varilrix™

Phase 2

Completed

Conditions: Varicella
Measles
Mumps
Rubella

First Posted Date: 2006-07-18

Last Posted Date: 2016-10-07

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 446

Registration Number: NCT00353288

Locations: 🇮🇹
GSK Investigational Site, Sassari, Sardegna, Italy

To Evaluate Safety & Reactogenicity of GSK Bio's Human Rotavirus (HRV) Vaccine in Filipino Infants at Least 6 Weeks of Age at First Vaccination

Completed

Conditions: Infections, Rotavirus
Rotavirus Vaccines

Interventions: Biological: Rotarix
Other: Data collection

First Posted Date: 2006-07-18

Last Posted Date: 2021-03-16

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 1439

Registration Number: NCT00353366

Locations: 🇵🇭
GSK Investigational Site, Taytay, Rizal, Philippines

Immunogenicity & Safety Study of Combined/Separate Vaccine(s) Against Common Diseases in Infants (2,4,6 Months of Age).

Phase 3

Completed

Conditions: Diphtheria
Tetanus
Poliomyelitis
Acellular Pertussis
Hepatitis B

First Posted Date: 2006-07-17

Last Posted Date: 2020-01-06

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 480

Registration Number: NCT00352963

Locations: 🇪🇸
GSK Investigational Site, Velez, Malaga, Spain

Immunogenicity, Safety of Measles-mumps-rubella-varicella Vaccine (MeMuRu-OKA) Compared to Priorix™ Given With Varilrix™

Phase 2

Completed

Conditions: Rubella
Varicella
Measles
Mumps

First Posted Date: 2006-07-17

Last Posted Date: 2016-10-07

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 400

Registration Number: NCT00352898

Locations: 🇮🇹
GSK Investigational Site, San Gregorio di Catania (CT), Sicilia, Italy

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy